CDKN2B and acute myeloid leukemia: In a phase 1 study of epigenetic priming with decitabine prior to cytotoxic therapy with cytarabine/daunorubicin in patients with AML, pre‐treatment and post‐priming DNA methylation levels of CDKN2B, LINE1, and HISTH2AA were not predictive of treatment response.[30]